Efficacy of a benzothiazole-based LRRK2 inhibitor in oligodendrocyte precursor cells and in a murine model of multiple sclerosis

Multiple sclerosis (MS) is a chronic neurological disease that currently lacks effective curative treatments. There is a need to find effective therapies, especially to reverse the progressive demyelination and neuronal damage. Oligodendrocytes form the myelin sheath around axons in the central nerv...

Descripción completa

Detalles Bibliográficos
Autores: Benítez-Fernández, Rocío, Josa-Prado, Fernando, Sánchez, Estefanía, Lao, Yolanda, García-Rubia, Alfonso, Cumella, José, Martínez, Ana, Palomo, Valle, Castro Soubriet, Fernando de
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/366896
Acceso en línea:http://hdl.handle.net/10261/366896
https://api.elsevier.com/content/abstract/scopus_id/85183030064
Access Level:acceso abierto
Palabra clave:LRRK2 inhibitors
multiple sclerosis
remyelinating agents
Descripción
Sumario:Multiple sclerosis (MS) is a chronic neurological disease that currently lacks effective curative treatments. There is a need to find effective therapies, especially to reverse the progressive demyelination and neuronal damage. Oligodendrocytes form the myelin sheath around axons in the central nervous system (CNS) and oligodendrocyte precursor cells (OPCs) undergo mechanisms that enable spontaneously the partial repair of damaged lesions. The aim of this study was to discover small molecules with potential effects in demyelinating diseases, including (re)myelinating properties.

Similares en LA Referencia